However, 31% of cancers showed ERBB2 deficiency in tumor samples, including prostate adenocarcinoma, kidney chromophobe, head-neck squamous cell carcinoma, renal clear cell carcinoma, colon adenocarcinoma, kidney renal papillary cell carcinoma, and lung squamous cell carcinoma (Figure S1A). Here, ERBB2 is linked to prostate adenocarcinoma.